Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Adaptimmune Therapeutics Plc ADR shares valued at $3,243 were sold by Norry Elliot on Jan 17 ’25. At $0.58 per share, Norry Elliot sold 5,584 shares. The insider’s holdings dropped to 7,510 shares worth approximately $2027.7 following the completion of this transaction.
Also, Lunger John sold 5,584 shares, netting a total of over 3,243 in proceeds. Following the sale of shares at $0.58 each, the insider now holds 7,510 shares.
Before that, Bertrand William C JR had sold 5,584 shares from its account. In a trade valued at $3,243, the Chief Operating Officer traded Adaptimmune Therapeutics Plc ADR shares for $0.58 each. Upon closing the transaction, the insider’s holdings decreased to 5,584 shares, worth approximately $2027.7.
As published in their initiating research note from H.C. Wainwright on July 30, 2024, Adaptimmune Therapeutics Plc ADR [ADAP] has been a Buy and the price target has been revised to $4. Analysts at Scotiabank started covering the stock with ‘”a Sector outperform”‘ outlook in a report released in late May. As of March 24, 2023, Bryan Garnier has initiated its “Buy” rating for ADAP. Earlier on January 03, 2023, Guggenheim upgraded its rating. Their new recommendation was “a Buy” for ADAP stock which previously was a “a Neutral”.
Analyzing ADAP Stock Performance
During the last five days, there has been a drop of approximately -9.33%. Over the course of the year, Adaptimmune Therapeutics Plc ADR shares have dropped approximately -49.51%. Shares of the company reached a 52-week high of $0.6850 on 01/06/25 and a 52-week low of $0.1951 on 04/01/25. A 50-day SMA is recorded $0.3057, while a 200-day SMA reached $0.6784.
Support And Resistance Levels for Adaptimmune Therapeutics Plc ADR (ADAP)
According to the 24-hour chart, there is a support level at 0.2511, which, if violated, would cause prices to drop to 0.2303. In the upper region, resistance lies at 0.2915. The next price resistance is at 0.3111. RSI (Relative Strength Index) is 46.27 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.0102, which suggests the price will decrease in the coming days. Percent R is at 67.66%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
